| pubmed-article:19389083 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19389083 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19389083 | lifeskim:mentions | umls-concept:C1556094 | lld:lifeskim |
| pubmed-article:19389083 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:19389083 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:19389083 | lifeskim:mentions | umls-concept:C0003385 | lld:lifeskim |
| pubmed-article:19389083 | lifeskim:mentions | umls-concept:C0878773 | lld:lifeskim |
| pubmed-article:19389083 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:19389083 | lifeskim:mentions | umls-concept:C1876226 | lld:lifeskim |
| pubmed-article:19389083 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:19389083 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:19389083 | pubmed:dateCreated | 2009-5-26 | lld:pubmed |
| pubmed-article:19389083 | pubmed:abstractText | To compare the efficacy and tolerability of imidafenacin, a novel antimuscarinic agent, with propiverine and a placebo in Japanese patients with overactive bladder (OAB). | lld:pubmed |
| pubmed-article:19389083 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19389083 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19389083 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19389083 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19389083 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19389083 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19389083 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19389083 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19389083 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19389083 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19389083 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19389083 | pubmed:month | May | lld:pubmed |
| pubmed-article:19389083 | pubmed:issn | 1442-2042 | lld:pubmed |
| pubmed-article:19389083 | pubmed:author | pubmed-author:HommaYukioY | lld:pubmed |
| pubmed-article:19389083 | pubmed:author | pubmed-author:YamaguchiOsam... | lld:pubmed |
| pubmed-article:19389083 | pubmed:author | pubmed-author:Imidafenacin... | lld:pubmed |
| pubmed-article:19389083 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19389083 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:19389083 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19389083 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19389083 | pubmed:pagination | 499-506 | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:meshHeading | pubmed-meshheading:19389083... | lld:pubmed |
| pubmed-article:19389083 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19389083 | pubmed:articleTitle | A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. | lld:pubmed |
| pubmed-article:19389083 | pubmed:affiliation | Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. homma-uro@umin.ac.jp | lld:pubmed |
| pubmed-article:19389083 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19389083 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:19389083 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:19389083 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19389083 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19389083 | lld:pubmed |
